fluoxetine has been researched along with Anorexia Nervosa in 52 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Anorexia Nervosa: An eating disorder that is characterized by the lack or loss of APPETITE, known as ANOREXIA. Other features include excess fear of becoming OVERWEIGHT; BODY IMAGE disturbance; significant WEIGHT LOSS; refusal to maintain minimal normal weight; and AMENORRHEA. This disorder occurs most frequently in adolescent females. (APA, Thesaurus of Psychological Index Terms, 1994)
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study failed to demonstrate any benefit from fluoxetine in the treatment of patients with anorexia nervosa following weight restoration." | 9.12 | Fluoxetine after weight restoration in anorexia nervosa: a randomized controlled trial. ( Attia, E; Carter, JC; Devlin, MJ; Kaplan, AS; Olmsted, M; Parides, M; Pike, KM; Roberto, CA; Rockert, W; Walsh, BT; Woodside, B, 2006) |
| "To evaluate the effectiveness of haloperidoll as an adjunctive treatment for resistant anorexia nervosa restricting subtype (AN-R)." | 9.10 | Six-month open trial of haloperidol as an adjunctive treatment for anorexia nervosa: a preliminary report. ( Banti, S; Borri, C; Camilleri, V; Cassano, GB; Mauri, M; Miniati, M; Pini, S; Rotondo, A, 2003) |
| "This study offers preliminary evidence that fluoxetine may be useful in improving outcome and preventing relapse of patients with anorexia nervosa after weight restoration." | 9.09 | Double-blind placebo-controlled administration of fluoxetine in restricting- and restricting-purging-type anorexia nervosa. ( Deep, D; Hsu, LK; Kaye, WH; McConaha, C; Nagata, T; Plotnicov, KH; Sokol, MS; Weise, J; Weltzin, TE, 2001) |
| "A six-week open label clinical trial investigated the response to fluoxetine in adolescents hospitalized for treatment of anorexia nervosa." | 9.09 | No effect of adjunctive fluoxetine on eating behavior or weight phobia during the inpatient treatment of anorexia nervosa: an historical case-control study. ( DeAntonio, M; Freeman, R; Pataki, C; Strober, M, 1999) |
| "Baseline concentrations of cholecystokinin-8 (CCK-8) and beta-endorphin (beta-EP) were measured in T-lymphocytes from 33 restricting patients with anorexia nervosa (AN-R), 23 binging/purging patients with anorexia nervosa (AN-BP), and 24 healthy volunteers." | 9.08 | T-lymphocyte cholecystokinin-8 and beta-endorphin concentrations in eating disorders: I. Anorexia nervosa. ( Brambilla, F; Brunetta, M; Manfredi, B; Panerai, AE; Peirone, A; Perna, G; Sacerdote, P, 1995) |
| "A 24-month naturalistic, prospective longitudinal followup study was conducted on 33 patients with anorexia nervosa who had participated in an intensive, multidisciplinary inpatient treatment program and were receiving fluoxetine as part of their continuing treatment regimen." | 9.08 | Does adjunctive fluoxetine influence the post-hospital course of restrictor-type anorexia nervosa? A 24-month prospective, longitudinal followup and comparison with historical controls. ( DeAntonio, M; Diamond, J; Freeman, R; Lampert, C; Strober, M, 1997) |
| "Fluoxetine does not appear to add significant benefit to the inpatient treatment of anorexia nervosa." | 9.08 | Does fluoxetine augment the inpatient treatment of anorexia nervosa? ( Attia, E; Flater, SR; Haiman, C; Walsh, BT, 1998) |
| "We administered an open trial of fluoxetine to 31 patients with DSM-III-R anorexia nervosa." | 9.07 | An open trial of fluoxetine in patients with anorexia nervosa. ( Bulik, CM; Hsu, LK; Kaye, WH; Weltzin, TE, 1991) |
| "Six patients with chronic, refractory anorexia nervosa were treated with fluoxetine." | 9.06 | Fluoxetine treatment of anorexia nervosa: an open clinical trial. ( Gainsley, B; Guze, BH; Gwirtsman, HE; Yager, J, 1990) |
| "The findings of this study will provide most recent evidence of fluoxetine for AN caused by chemotherapy in patients with cholangiocarcinoma." | 9.01 | Efficacy of fluoxetine for anorexia nervosa caused by chemotherapy in patients with cholangiocarcinoma. ( Feng, Y; Guo, LQ; Qu, YK; Sun, HW; Teng, XL; Zhang, CY, 2019) |
| "Literature was accessed via PubMed through June 2013 using the terms fluoxetine and anorexia nervosa." | 8.89 | Use of fluoxetine in anorexia nervosa before and after weight restoration. ( Cox, S; Garris, SS; Hughes, CM; Kennedy, ML; Sebaaly, JC, 2013) |
| "To evaluate the efficacy of fluoxetine in the treatment of anorexia nervosa." | 8.82 | Role of fluoxetine in anorexia nervosa. ( Kim, SS, 2003) |
| "This report describes a case of 12-year-old identical twins with anorexia nervosa, one of whom was treated with olanzapine and the other with fluoxetine, while undergoing family therapy." | 7.78 | Differential weight restoration on olanzapine versus fluoxetine in identical twins with anorexia nervosa. ( Boutelle, K; Cromley, T; Duvvuri, V; Kaye, WH; Klabunde, M, 2012) |
| "Stomatitis related to fluoxetine has not been previously reported in clinical trials or in the literature." | 7.69 | Fluoxetine-associated stomatitis. ( Martínez-Mir, I; Morales-Olivas, FJ; Palop, V; Sancho, A, 1997) |
| "Anorexia nervosa is associated with vasopressin, oxytocin and serotonin abnormalities." | 7.68 | Fluoxetine induces vasopressin and oxytocin abnormalities in food-restricted rats given voluntary exercise: relationship to anorexia nervosa. ( Ahmed, I; Aravich, PF; Lauterio, TJ; Rieg, TS, 1993) |
| "Following weight restoration in an acute care setting, 93 women with anorexia nervosa were randomly assigned to receive fluoxetine or placebo and were discharged to outpatient care, where they also received cognitive-behavioral therapy for up to 1 year." | 5.41 | Time Course of Relapse Following Acute Treatment for Anorexia Nervosa. ( Attia, E; Kaplan, AS; Walsh, BT; Wang, Y; Xu, T, 2021) |
| "Body composition and fasting cortisol and leptin levels were assessed before random assignment in 32 weight-recovered subjects with anorexia nervosa from the New York site of the Fluoxetine to Prevent Relapse in Women With Anorexia Nervosa trial." | 5.12 | Does percent body fat predict outcome in anorexia nervosa? ( Attia, E; Devlin, MJ; Etu, SF; Gallagher, D; Glasofer, DR; Heymsfield, SB; Mayer, LE; Pierson, RN; Roberto, CA; Walsh, BT; Wang, J, 2007) |
| "This study failed to demonstrate any benefit from fluoxetine in the treatment of patients with anorexia nervosa following weight restoration." | 5.12 | Fluoxetine after weight restoration in anorexia nervosa: a randomized controlled trial. ( Attia, E; Carter, JC; Devlin, MJ; Kaplan, AS; Olmsted, M; Parides, M; Pike, KM; Roberto, CA; Rockert, W; Walsh, BT; Woodside, B, 2006) |
| "To evaluate the effectiveness of haloperidoll as an adjunctive treatment for resistant anorexia nervosa restricting subtype (AN-R)." | 5.10 | Six-month open trial of haloperidol as an adjunctive treatment for anorexia nervosa: a preliminary report. ( Banti, S; Borri, C; Camilleri, V; Cassano, GB; Mauri, M; Miniati, M; Pini, S; Rotondo, A, 2003) |
| "The efficacy of venlafaxine and fluoxetine in the treatment of atypical anorexia nervosa (AN) was compared in a controlled trial." | 5.09 | Venlafaxine versus fluoxetine in the treatment of atypical anorectic outpatients: a preliminary study. ( Cabras, PL; Cellini, M; Di Bernardo, M; Mannucci, E; Paionni, A; Ricca, V; Rotella, CM, 1999) |
| "This study offers preliminary evidence that fluoxetine may be useful in improving outcome and preventing relapse of patients with anorexia nervosa after weight restoration." | 5.09 | Double-blind placebo-controlled administration of fluoxetine in restricting- and restricting-purging-type anorexia nervosa. ( Deep, D; Hsu, LK; Kaye, WH; McConaha, C; Nagata, T; Plotnicov, KH; Sokol, MS; Weise, J; Weltzin, TE, 2001) |
| " The study evaluated the efficacy of amisulpride, fluoxetine and clomipramine at the beginning of the re-feeding phase of the treatment of restricting anorexia nervosa according to DSM-IV criteria." | 5.09 | A single blind comparison of amisulpride, fluoxetine and clomipramine in the treatment of restricting anorectics. ( Cavagnini, F; Clemente, A; Ferrari, VM; Laini, V; Lugo, F; Mantero, M; Mauri, MC; Redaelli, G; Ruggiero, GM; Zappulli, D, 2001) |
| "Twenty-two female patients with anorexia nervosa, restricted type, 14-35 years old, were treated with a 4-month course of combined cognitive-behavioral therapy, nutritional counselling and antidepressant drugs (nortriptyline for 7, fluoxetine for 15)." | 5.08 | Combined cognitive-behavioral, psychopharmacological and nutritional therapy in eating disorders. 1. Anorexia nervosa--restricted type. ( Brambilla, F; Brunetta, M; Draisci, A; Peirone, A, 1995) |
| "Fluoxetine does not appear to add significant benefit to the inpatient treatment of anorexia nervosa." | 5.08 | Does fluoxetine augment the inpatient treatment of anorexia nervosa? ( Attia, E; Flater, SR; Haiman, C; Walsh, BT, 1998) |
| "Baseline concentrations of cholecystokinin-8 (CCK-8) and beta-endorphin (beta-EP) were measured in T-lymphocytes from 33 restricting patients with anorexia nervosa (AN-R), 23 binging/purging patients with anorexia nervosa (AN-BP), and 24 healthy volunteers." | 5.08 | T-lymphocyte cholecystokinin-8 and beta-endorphin concentrations in eating disorders: I. Anorexia nervosa. ( Brambilla, F; Brunetta, M; Manfredi, B; Panerai, AE; Peirone, A; Perna, G; Sacerdote, P, 1995) |
| "We administered an open trial of fluoxetine to 31 patients with DSM-III-R anorexia nervosa." | 5.07 | An open trial of fluoxetine in patients with anorexia nervosa. ( Bulik, CM; Hsu, LK; Kaye, WH; Weltzin, TE, 1991) |
| "Six patients with chronic, refractory anorexia nervosa were treated with fluoxetine." | 5.06 | Fluoxetine treatment of anorexia nervosa: an open clinical trial. ( Gainsley, B; Guze, BH; Gwirtsman, HE; Yager, J, 1990) |
| " Antidepressants are commonly used to treat bulimia nervosa; high-dose fluoxetine is a standard approach, but many other antidepressants can be used." | 5.01 | Pharmacologic Treatment of Eating Disorders. ( Crow, SJ, 2019) |
| "The findings of this study will provide most recent evidence of fluoxetine for AN caused by chemotherapy in patients with cholangiocarcinoma." | 5.01 | Efficacy of fluoxetine for anorexia nervosa caused by chemotherapy in patients with cholangiocarcinoma. ( Feng, Y; Guo, LQ; Qu, YK; Sun, HW; Teng, XL; Zhang, CY, 2019) |
| "Literature was accessed via PubMed through June 2013 using the terms fluoxetine and anorexia nervosa." | 4.89 | Use of fluoxetine in anorexia nervosa before and after weight restoration. ( Cox, S; Garris, SS; Hughes, CM; Kennedy, ML; Sebaaly, JC, 2013) |
| "This report describes a case of 12-year-old identical twins with anorexia nervosa, one of whom was treated with olanzapine and the other with fluoxetine, while undergoing family therapy." | 3.78 | Differential weight restoration on olanzapine versus fluoxetine in identical twins with anorexia nervosa. ( Boutelle, K; Cromley, T; Duvvuri, V; Kaye, WH; Klabunde, M, 2012) |
| "Stomatitis related to fluoxetine has not been previously reported in clinical trials or in the literature." | 3.69 | Fluoxetine-associated stomatitis. ( Martínez-Mir, I; Morales-Olivas, FJ; Palop, V; Sancho, A, 1997) |
| "Anorexia nervosa is associated with vasopressin, oxytocin and serotonin abnormalities." | 3.68 | Fluoxetine induces vasopressin and oxytocin abnormalities in food-restricted rats given voluntary exercise: relationship to anorexia nervosa. ( Ahmed, I; Aravich, PF; Lauterio, TJ; Rieg, TS, 1993) |
| "A number of symptoms associated with eating disorders overlap those of depression and OCD, suggesting a theoretical and practical case for evaluating the SSRIs in the treatment of anorexia nervosa, bulimia nervosa, binge-eating disorder, and obesity." | 2.40 | The use of selective serotonin reuptake inhibitors in eating disorders. ( Mayer, LE; Walsh, BT, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (3.85) | 18.7374 |
| 1990's | 22 (42.31) | 18.2507 |
| 2000's | 18 (34.62) | 29.6817 |
| 2010's | 8 (15.38) | 24.3611 |
| 2020's | 2 (3.85) | 2.80 |
| Authors | Studies |
|---|---|
| Fornaro, M | 1 |
| Mondin, AM | 1 |
| Billeci, M | 1 |
| Fusco, A | 1 |
| De Prisco, M | 1 |
| Caiazza, C | 1 |
| Micanti, F | 1 |
| Calati, R | 1 |
| Carvalho, AF | 1 |
| de Bartolomeis, A | 1 |
| Walsh, BT | 6 |
| Xu, T | 1 |
| Wang, Y | 1 |
| Attia, E | 5 |
| Kaplan, AS | 4 |
| Himmerich, H | 1 |
| Treasure, J | 1 |
| Crow, SJ | 3 |
| Guo, LQ | 1 |
| Sun, HW | 1 |
| Zhang, CY | 1 |
| Feng, Y | 1 |
| Teng, XL | 1 |
| Qu, YK | 1 |
| Sebaaly, JC | 1 |
| Cox, S | 1 |
| Hughes, CM | 1 |
| Kennedy, ML | 1 |
| Garris, SS | 1 |
| Olmsted, M | 2 |
| Carter, JC | 2 |
| Devlin, MJ | 3 |
| Pike, KM | 2 |
| Woodside, B | 3 |
| Rockert, W | 2 |
| Roberto, CA | 3 |
| Parides, M | 2 |
| Duvvuri, V | 1 |
| Cromley, T | 1 |
| Klabunde, M | 1 |
| Boutelle, K | 1 |
| Kaye, WH | 4 |
| Lock, J | 1 |
| Brandt, H | 1 |
| Agras, S | 1 |
| Halmi, WK | 1 |
| Johnson, C | 1 |
| Kaye, W | 2 |
| Wilfley, D | 1 |
| Lee, CW | 1 |
| Park, MI | 1 |
| Park, SJ | 1 |
| Moon, W | 1 |
| Kim, HH | 1 |
| Kim, BJ | 1 |
| Shim, IK | 1 |
| Park, SS | 1 |
| Yu, J | 1 |
| Stewart Agras, W | 1 |
| Halmi, KA | 3 |
| Crow, S | 2 |
| Mitchell, J | 2 |
| Bryson, SW | 2 |
| Cassano, GB | 1 |
| Miniati, M | 1 |
| Pini, S | 1 |
| Rotondo, A | 1 |
| Banti, S | 1 |
| Borri, C | 1 |
| Camilleri, V | 1 |
| Mauri, M | 1 |
| Kim, SS | 1 |
| Barbarich, NC | 1 |
| McConaha, CW | 1 |
| Gendall, K | 1 |
| Sunday, SR | 1 |
| Gaskill, J | 1 |
| La Via, M | 1 |
| Frank, GK | 1 |
| Brooks, S | 1 |
| Plotnicov, KH | 2 |
| McDermott, C | 1 |
| Agras, WS | 2 |
| Halmi, K | 1 |
| Mitchell, JE | 1 |
| Bryson, S | 1 |
| Fairburn, CG | 1 |
| Menaster, M | 1 |
| Wilson, GT | 1 |
| Kraemer, HC | 1 |
| Sokol, MS | 2 |
| Fujimoto, CK | 1 |
| Jackson, TK | 1 |
| Silberberg, PJ | 1 |
| Cavedini, P | 1 |
| Zorzi, C | 1 |
| Bassi, T | 1 |
| Gorini, A | 1 |
| Baraldi, C | 1 |
| Ubbiali, A | 1 |
| Bellodi, L | 1 |
| Dettling, M | 1 |
| Opgen-Rhein, C | 1 |
| Quante, A | 1 |
| Anghelescu, I | 1 |
| Mayer, LE | 2 |
| Glasofer, DR | 1 |
| Etu, SF | 1 |
| Gallagher, D | 1 |
| Wang, J | 1 |
| Heymsfield, SB | 1 |
| Pierson, RN | 1 |
| Brambilla, F | 2 |
| Draisci, A | 1 |
| Peirone, A | 2 |
| Brunetta, M | 2 |
| Weltzin, TE | 3 |
| McCabe, E | 1 |
| Flynn, D | 1 |
| Vaz, FJ | 1 |
| Salcedo, MS | 1 |
| Aravich, PF | 1 |
| Rieg, TS | 1 |
| Ahmed, I | 1 |
| Lauterio, TJ | 1 |
| Jarry, JL | 1 |
| Vaccarino, FJ | 1 |
| Pryor, TL | 1 |
| Martin, RL | 1 |
| Roach, N | 1 |
| Perna, G | 1 |
| Sacerdote, P | 1 |
| Manfredi, B | 1 |
| Panerai, AE | 1 |
| Bergh, C | 1 |
| Eriksson, M | 1 |
| Lindberg, G | 1 |
| Södersten, P | 1 |
| Bostic, JQ | 1 |
| Muriel, AC | 1 |
| Hack, S | 1 |
| Weinstein, S | 1 |
| Herzog, D | 1 |
| Palop, V | 1 |
| Sancho, A | 1 |
| Morales-Olivas, FJ | 1 |
| Martínez-Mir, I | 1 |
| Haiman, C | 1 |
| Flater, SR | 1 |
| Strober, M | 2 |
| Freeman, R | 2 |
| DeAntonio, M | 2 |
| Lampert, C | 1 |
| Diamond, J | 1 |
| Yager, J | 2 |
| Siegfreid, SL | 1 |
| DiMatteo, TL | 1 |
| Pataki, C | 1 |
| Morgan, JF | 1 |
| Ricca, V | 1 |
| Mannucci, E | 1 |
| Paionni, A | 1 |
| Di Bernardo, M | 1 |
| Cellini, M | 1 |
| Cabras, PL | 1 |
| Rotella, CM | 1 |
| Harel, Z | 1 |
| Hallett, J | 1 |
| Riggs, S | 1 |
| Vaz, R | 1 |
| Kiessling, L | 1 |
| Nagata, T | 1 |
| Hsu, LK | 2 |
| McConaha, C | 1 |
| Weise, J | 1 |
| Deep, D | 1 |
| Ruggiero, GM | 1 |
| Laini, V | 1 |
| Mauri, MC | 1 |
| Ferrari, VM | 1 |
| Clemente, A | 1 |
| Lugo, F | 1 |
| Mantero, M | 1 |
| Redaelli, G | 1 |
| Zappulli, D | 1 |
| Cavagnini, F | 1 |
| Oliveros, SC | 1 |
| Iruela, LM | 1 |
| Caballero, L | 1 |
| Baca, E | 1 |
| Bulik, CM | 1 |
| Lee, S | 1 |
| Gwirtsman, HE | 1 |
| Guze, BH | 1 |
| Gainsley, B | 1 |
| Lyles, B | 1 |
| Sarkis, E | 1 |
| Kemph, JP | 1 |
| Wilcox, JA | 1 |
| Ferguson, JM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Identifying Networks Underlying Compulsivity in Anorexia Nervosa for Targeting With Neuromodulation[NCT06138782] | 20 participants (Anticipated) | Interventional | 2023-10-16 | Recruiting | |||
| Family Therapy in the Treatment of Adolescent Anorexia Nervosa[NCT00610753] | Phase 3 | 164 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| Fluoxetine After Weight Restoration in Anorexia Nervosa[NCT00288574] | Phase 4 | 93 participants (Actual) | Interventional | 2000-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00288574)
Timeframe: 12 months
| Intervention | kg per month (Mean) |
|---|---|
| Fluoxetine | -1.94 |
| Placebo | -2.14 |
The Beck Anxiety Inventory is a 21 question self-report measure of anxiety symptoms during the past week. Possible scores range from 0 - 63, with higher scores indicating more severe symptoms. Random effects regression models were used to compare fluoxetine vs placebo groups over time, using data from all patients. (NCT00288574)
Timeframe: 12 months
| Intervention | units on a scale (Mean) |
|---|---|
| Fluoxetine | -0.70 |
| Placebo | -0.22 |
The Beck Depression Inventory-II is a 21 question self-report measure of depressive symptoms. Possible scores range from 0 - 63, with higher scores indicating more severe symptoms.Random effects regression models were used to compare fluoxetine vs placebo groups over time, using data from all patients. (NCT00288574)
Timeframe: 12 months
| Intervention | units on a scale (Mean) |
|---|---|
| Fluoxetine | 0.12 |
| Placebo | 0.20 |
The EDI is a 64 item self-report measure of psychological and behavioral characteristics of eating disorders. The Body Dissatisfaction subscale is comprised of nine items indicating the belief that parts of the body are too large. Possible scores range from 0 to 27, with higher scores indicating greater dissatisfaction. Random effects regression models were used to compare fluoxetine vs placebo groups over time, using data from all patients. (NCT00288574)
Timeframe: 12 months
| Intervention | units on a scale (Mean) |
|---|---|
| Fluoxetine | -0.24 |
| Placebo | -0.26 |
The EDI is a 64 item self-report measure of psychological and behavioral characteristics of eating disorders. The Bulimia subscale is comprised of seven items indicating the tendency towards episodes of uncontrollable overeating (binge eating). Possible scores range from 0 to 21, with higher scores indicating greater tendency. Random effects regression models were used to compare fluoxetine vs placebo groups over time, using data from all patients. (NCT00288574)
Timeframe: 12 months
| Intervention | units on a scale (Mean) |
|---|---|
| Fluoxetine | -0.11 |
| Placebo | 0.035 |
The EDI is a 64 item self-report measure of psychological and behavioral characteristics of eating disorders. The Drive for Thinness subscale is comprised of seven items indicating excessive concern with dieting, preoccupation with weight and entrenchment in an extreme pursuit of thinness. Possible scores range from 0 to 21, with higher scores indicating greater Drive for Thinness. Random effects regression models were used to compare fluoxetine vs placebo groups over time, using data from all patients. (NCT00288574)
Timeframe: 12 months
| Intervention | units on a scale (Mean) |
|---|---|
| Fluoxetine | -0.24 |
| Placebo | -0.81 |
The EDI is a 64 item self-report measure of psychological and behavioral characteristics of eating disorders. The Perfectionism subscale is comprised of six items Indicating excessive personal expectations for superior achievement. Possible scores range from 0 to 18, with higher scores indicating greater expectations. Random effects regression models were used to compare fluoxetine vs placebo groups over time, using data from all patients. (NCT00288574)
Timeframe: 12 months
| Intervention | units on a scale (Mean) |
|---|---|
| Fluoxetine | -0.037 |
| Placebo | 0.05 |
The Q-LES-Q is a 93 item self-report measure of enjoyment and satisfaction experienced by individuals in various areas of daily functioning. Each of the 93 items is scored on a five-point scale, and the total score is converted to a percentage of the maximum score possible. The range is therefore from 0 to 100, with a higher score indicating greater enjoyment or satisfaction. Random effects regression models were used to compare fluoxetine vs placebo groups over time, using data from all patients. (NCT00288574)
Timeframe: 12 months
| Intervention | percentage of maximum possible score (Mean) |
|---|---|
| Fluoxetine | 0.23 |
| Placebo | 0.31 |
The RSES is a 10 item self-report measure of self-esteem. Possible scores range from 0 - 30, with lower scores indicating more severe symptoms. Random effects regression models were used to compare fluoxetine vs placebo groups over time, using data from all patients. (NCT00288574)
Timeframe: 12 months
| Intervention | units on a scale (Mean) |
|---|---|
| Fluoxetine | 0.12 |
| Placebo | 0.07 |
The YBC-EDS is an eight item, clinician-rated instrument assessing eating related preoccupations and/or rituals. Possible scores range from 0 to 32, with higher scores indicating greater preoccupations. Random effects regression models were used to compare fluoxetine vs placebo groups over time, using data from all patients. (NCT00288574)
Timeframe: 12 months
| Intervention | units on a scale (Mean) |
|---|---|
| Fluoxetine | -0.18 |
| Placebo | 0.028 |
The primary outcome measure was the proportion of patients with AN successfully completing 1 year of treatment and maintaining > 85% Ideal Body Weight. (NCT00288574)
Timeframe: 12 months
| Intervention | proportion of participants (Number) |
|---|---|
| Fluoxetine | 0.265 |
| Placebo | 0.315 |
10 reviews available for fluoxetine and Anorexia Nervosa
| Article | Year |
|---|---|
Psychopharmacology of eating disorders: Systematic review and meta-analysis of randomized controlled trials.
Topics: Anorexia Nervosa; Antipsychotic Agents; Binge-Eating Disorder; Bulimia Nervosa; Feeding and Eating D | 2023 |
Psychopharmacological advances in eating disorders.
Topics: Animals; Anorexia Nervosa; Binge-Eating Disorder; Bulimia Nervosa; Drug Design; Fluoxetine; Humans; | 2018 |
Pharmacologic Treatment of Eating Disorders.
Topics: Anorexia Nervosa; Antidepressive Agents, Second-Generation; Binge-Eating Disorder; Bulimia Nervosa; | 2019 |
Efficacy of fluoxetine for anorexia nervosa caused by chemotherapy in patients with cholangiocarcinoma.
Topics: Anorexia Nervosa; Antidepressive Agents, Second-Generation; Antineoplastic Agents; Bile Duct Neoplas | 2019 |
Use of fluoxetine in anorexia nervosa before and after weight restoration.
Topics: Anorexia Nervosa; Antidepressive Agents, Second-Generation; Body Weight; Fluoxetine; Humans; Selecti | 2013 |
Role of fluoxetine in anorexia nervosa.
Topics: Animals; Anorexia Nervosa; Clinical Trials as Topic; Fluoxetine; Humans | 2003 |
Evidence-based treatment of anorexia nervosa.
Topics: Adolescent; Ambulatory Care; Anorexia Nervosa; Combined Modality Therapy; Counseling; Fluoxetine; Ho | 2005 |
Eating disorder and obsessive-compulsive disorder: neurochemical and phenomenological commonalities.
Topics: Anorexia Nervosa; Bulimia; Clomipramine; Comorbidity; Female; Fluoxetine; Humans; Male; Obsessive-Co | 1996 |
The use of selective serotonin reuptake inhibitors in eating disorders.
Topics: Anorexia Nervosa; Antidepressive Agents; Bulimia; Clinical Trials as Topic; Combined Modality Therap | 1998 |
Psychological treatments for anorexia nervosa: a review of published studies and promising new directions.
Topics: Anorexia Nervosa; Combined Modality Therapy; Female; Fluoxetine; Humans; Psychotherapy; Randomized C | 2002 |
19 trials available for fluoxetine and Anorexia Nervosa
| Article | Year |
|---|---|
Time Course of Relapse Following Acute Treatment for Anorexia Nervosa.
Topics: Adolescent; Adult; Anorexia Nervosa; Cognitive Behavioral Therapy; Combined Modality Therapy; Female | 2021 |
The slippery slope: prediction of successful weight maintenance in anorexia nervosa.
Topics: Adolescent; Adult; Anorexia Nervosa; Body Image; Body Mass Index; Body Weight; Cognitive Behavioral | 2009 |
A 1-year follow-up of a multi-center treatment trial of adults with anorexia nervosa.
Topics: Adult; Anorexia Nervosa; Body Weight; Cognitive Behavioral Therapy; Combined Modality Therapy; Femal | 2011 |
Six-month open trial of haloperidol as an adjunctive treatment for anorexia nervosa: a preliminary report.
Topics: Adrenergic Uptake Inhibitors; Adult; Amitriptyline; Anorexia Nervosa; Body Mass Index; Dopamine Anta | 2003 |
Use of nutritional supplements to increase the efficacy of fluoxetine in the treatment of anorexia nervosa.
Topics: Adult; Anorexia Nervosa; Combined Modality Therapy; Dietary Supplements; Docosahexaenoic Acids; Doub | 2004 |
Participant recruitment for an anorexia nervosa treatment study.
Topics: Adolescent; Adult; Anorexia Nervosa; Bulimia; Cognitive Behavioral Therapy; Combined Modality Therap | 2004 |
Predictors of treatment acceptance and completion in anorexia nervosa: implications for future study designs.
Topics: Adolescent; Adult; Anorexia Nervosa; Cognitive Behavioral Therapy; Combined Modality Therapy; Female | 2005 |
Fluoxetine after weight restoration in anorexia nervosa: a randomized controlled trial.
Topics: Adolescent; Adult; Anorexia Nervosa; Antidepressive Agents, Second-Generation; Body Mass Index; Cogn | 2006 |
Does percent body fat predict outcome in anorexia nervosa?
Topics: Adipose Tissue; Adiposity; Adolescent; Adult; Anorexia Nervosa; Body Mass Index; Female; Fluoxetine; | 2007 |
Combined cognitive-behavioral, psychopharmacological and nutritional therapy in eating disorders. 1. Anorexia nervosa--restricted type.
Topics: Adolescent; Adult; Anorexia Nervosa; Antidepressive Agents, Second-Generation; Antidepressive Agents | 1995 |
T-lymphocyte cholecystokinin-8 and beta-endorphin concentrations in eating disorders: I. Anorexia nervosa.
Topics: Adolescent; Adult; Anorexia Nervosa; Antidepressive Agents; beta-Endorphin; Child; Cognitive Behavio | 1995 |
Does fluoxetine augment the inpatient treatment of anorexia nervosa?
Topics: Adolescent; Adult; Anorexia Nervosa; Body Weight; Combined Modality Therapy; Depressive Disorder; Do | 1998 |
Does adjunctive fluoxetine influence the post-hospital course of restrictor-type anorexia nervosa? A 24-month prospective, longitudinal followup and comparison with historical controls.
Topics: Adolescent; Adult; Anorexia Nervosa; Antidepressive Agents, Second-Generation; Female; Fluoxetine; H | 1997 |
No effect of adjunctive fluoxetine on eating behavior or weight phobia during the inpatient treatment of anorexia nervosa: an historical case-control study.
Topics: Adolescent; Analysis of Variance; Anorexia Nervosa; Case-Control Studies; Chemotherapy, Adjuvant; Co | 1999 |
Venlafaxine versus fluoxetine in the treatment of atypical anorectic outpatients: a preliminary study.
Topics: Adolescent; Adult; Anorexia Nervosa; Antidepressive Agents, Second-Generation; Cognitive Behavioral | 1999 |
Double-blind placebo-controlled administration of fluoxetine in restricting- and restricting-purging-type anorexia nervosa.
Topics: Adolescent; Adult; Anorexia Nervosa; Double-Blind Method; Female; Fluoxetine; Humans; Secondary Prev | 2001 |
A single blind comparison of amisulpride, fluoxetine and clomipramine in the treatment of restricting anorectics.
Topics: Adult; Amenorrhea; Amisulpride; Anorexia Nervosa; Antidepressive Agents, Second-Generation; Antidepr | 2001 |
An open trial of fluoxetine in patients with anorexia nervosa.
Topics: Adolescent; Adult; Ambulatory Care; Anorexia Nervosa; Body Weight; Bulimia; Female; Fluoxetine; Foll | 1991 |
Fluoxetine treatment of anorexia nervosa: an open clinical trial.
Topics: Adult; Anorexia Nervosa; Body Weight; Contraindications; Depressive Disorder; Female; Fluoxetine; Hu | 1990 |
23 other studies available for fluoxetine and Anorexia Nervosa
| Article | Year |
|---|---|
Differential weight restoration on olanzapine versus fluoxetine in identical twins with anorexia nervosa.
Topics: Anorexia Nervosa; Benzodiazepines; Child; Diseases in Twins; Family Therapy; Female; Fluoxetine; Hum | 2012 |
Challenges in conducting a multi-site randomized clinical trial comparing treatments for adolescent anorexia nervosa.
Topics: Adolescent; Anorexia Nervosa; Behavior Therapy; Family Therapy; Female; Fluoxetine; Humans; Patient | 2012 |
[A case of superior mesenteric artery syndrome caused by anorexia nervosa].
Topics: Adolescent; Anorexia Nervosa; Antidepressive Agents; Cognitive Behavioral Therapy; Endoscopy, Gastro | 2011 |
Use of olanzapine in anorexia nervosa.
Topics: Anorexia Nervosa; Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Fluoxetine; Human | 2005 |
Fluoxetine treatment of anorexia nervosa: important but disappointing results.
Topics: Anorexia Nervosa; Antidepressive Agents, Second-Generation; Fluoxetine; Humans; Selective Serotonin | 2006 |
Anorexia nervosa and brain tumor in a 14-year-old girl.
Topics: Adolescent; Anorexia Nervosa; Brain Neoplasms; Depression; Female; Fluoxetine; Humans; Magnetic Reso | 2006 |
Decision-making functioning as a predictor of treatment outcome in anorexia nervosa.
Topics: Adult; Anorexia Nervosa; Body Mass Index; Cognition Disorders; Cognitive Behavioral Therapy; Combine | 2006 |
Fluoxetine for treatment of anorexia nervosa.
Topics: Anorexia Nervosa; Antidepressive Agents, Second-Generation; Fluoxetine; Humans; Selective Serotonin | 2006 |
Anorexia and bulimia nervosa: psychiatric approach.
Topics: Anorexia Nervosa; Antidepressive Agents; Bulimia; Cyproheptadine; Fluoxetine; Humans; Nutritional Ph | 1994 |
Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa.
Topics: Adult; Anorexia; Anorexia Nervosa; Bulimia; Drug Administration Schedule; Female; Fluoxetine; Humans | 1994 |
Fluoxetine induces vasopressin and oxytocin abnormalities in food-restricted rats given voluntary exercise: relationship to anorexia nervosa.
Topics: Animals; Anorexia Nervosa; Behavior, Animal; Body Weight; Dynorphins; Eating; Fluoxetine; Male; Oxyt | 1993 |
Obsessive-compulsive disorder, trichotillomania, and anorexia nervosa: a case report.
Topics: Adolescent; Anorexia Nervosa; Combined Modality Therapy; Female; Fluoxetine; Humans; Obsessive-Compu | 1995 |
Selective serotonin reuptake inhibitors in anorexia nervosa.
Topics: Anorexia Nervosa; Fluoxetine; Humans; Selective Serotonin Reuptake Inhibitors | 1997 |
Anorexia nervosa in a 7-year-old girl.
Topics: Age of Onset; Anorexia Nervosa; Antidepressive Agents, Second-Generation; Child; Depression; Female; | 1997 |
Fluoxetine-associated stomatitis.
Topics: Adult; Anorexia Nervosa; Antidepressive Agents, Second-Generation; Depression; Female; Fluoxetine; H | 1997 |
Use of alternative remedies by psychiatric patients: illustrative vignettes and a discussion of the issues.
Topics: Adult; Anorexia Nervosa; Cognitive Behavioral Therapy; Combined Modality Therapy; Complementary Ther | 1999 |
Fluoxetine and eating disorders.
Topics: Anorexia Nervosa; Fluoxetine; Humans; Selective Serotonin Reuptake Inhibitors | 1999 |
Antibodies against human putamen in adolescents with anorexia nervosa.
Topics: Adolescent; Anorexia Nervosa; Antibodies; Benzodiazepines; Body Mass Index; Caudate Nucleus; Enzyme- | 2001 |
Fluoxetine-induced anorexia in a bulimic patient.
Topics: Adult; Amenorrhea; Anorexia Nervosa; Bulimia; Female; Fluoxetine; Humans; Recurrence; Weight Gain | 1992 |
Fluoxetine in anorexia nervosa.
Topics: Anorexia Nervosa; Depressive Disorder; Female; Fluoxetine; Humans; Obsessive-Compulsive Disorder | 1991 |
Fluoxetine and anorexia.
Topics: Adolescent; Anorexia Nervosa; Bulimia; Combined Modality Therapy; Depressive Disorder; Female; Fluox | 1990 |
Abuse of fluoxetine by a patient with anorexia nervosa.
Topics: Adult; Anorexia Nervosa; Body Weight; Depressive Disorder; Female; Fluoxetine; Humans; Propylamines; | 1987 |
Treatment of an anorexia nervosa patient with fluoxetine.
Topics: Adult; Anorexia Nervosa; Antidepressive Agents; Female; Fluoxetine; Humans; Propylamines | 1987 |